Strategic Valuation Network: 1 book

Cover of Exact Sciences Corporation

Exact Sciences Corporation

Strategic Valuation, #1

by Strategic Valuation
Language: English
Release Date: November 17, 2017

Exact Sciences Corporation (EXAS) is a publicly traded molecular diagnostics company focused on the early detection and prevention of colon cancer. EXAS has developed, and currently commercializes the Cologuard test, a non-invasive stool-based deoxyribonucleic acid screening test designed to detect...
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy